Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno , the company’s chief financial officer, is scheduled to present a company overview at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference on Tuesday, June 23, 2020 at 10:30 a.m. Eastern Time . To access the live and subs
SOUTH SAN FRANCISCO, Calif., June 17, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc., Inc. (Nasdaq: RIGL) today announced that Dean Schorno, the company's chief financial officer, is scheduled to present a company overview at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference on Tuesday, June 23, 2020 at 10:30 a.m. Eastern Time. To access the live and subsequently archived webcast, go to the Investor Relations section of the company's website at www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary. About Rigel (www.rigel.com) Rigel's clinical programs include a Phase 3 study of fostamatinib in warm autoimmune hemolytic anemia (wAIHA); a completed Phase 1 study of R8351, a proprietary molecule from its interleukin receptor associated kinase (IRAK) inhibitor program; and an ongoing Phase 1 study of R5521, a proprietary molecule from its receptor-interacting protein kinase (RIP) inhibitor program. In addition, Rigel has product candidates in clinical development with partners Aclaris Therapeutics, AstraZeneca, BerGenBio ASA, and Daiichi Sankyo. Please see www.TAVALISSE.com for the full Prescribing Information. 1This product candidate is investigational and has not been established safe or effective by the U.S. Food and Drug Administration (FDA) or any regulatory authority. Contact: David Burke
SOURCE Rigel Pharmaceuticals, Inc. |
||
Company Codes: NASDAQ-NMS:RIGL |